EP-4734947-A1 - A PERSONAL CARE COMPOSITION

Abstract

Disclosed is a personal care composition comprising carboxymethyl cysteine compound and moringa oil wherein the carboxymethyl cysteine compound is present in amount of at least 0.00001% and no greater than 10% by weight of the composition.

Inventors

• GU, Xuelan
• XIAO, XUE

Assignees

• Unilever IP Holdings B.V.
• UNILEVER GLOBAL IP LIMITED

Dates

Publication Date

20260506

Application Date

20240606

Claims (14)

1. 1. A personal care composition comprising carboxymethyl cysteine compound and moringa oil, wherein the carboxymethyl cysteine compound is present in amount of at least 0.00001% and no greater than 10% by weight of the composition.
2. 2. The composition according to claim 1 wherein the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and/or salt of carboxymethyl cysteine.
3. 3. The composition according to claim 2 wherein the carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine and preferably the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate.
4. 4. The composition according to any one of the preceding claims wherein the carboxymethyl cysteine compound is present in amount of at least 0.01% and no greater than 3% by weight of the composition.
5. 5. The composition according to any one of the preceding claims wherein the moringa oil comprises or is moringa seed oil.
6. 6. The composition according to any one of the preceding claims wherein the moringa oil is extracted from the seeds of Moringa Oleifera.
7. 7. The composition as claimed in any one of the preceding claims wherein the moringa oil is present in amount of 0.0001 to 10%, more preferably 0.012 to 1.5% by weight of the composition.
8. 8. The composition according to any one of the preceding claims wherein the weight ratio of the carboxymethyl cysteine compound to moringa oil is in the range of 1 :500 to 1 :3, preferably in the range of 1 : 100 to 1 :30.
9. 9. The composition according to any one of the preceding claims wherein the composition is an emulsion, preferably an oil-in-water emulsion.
10. 10. The composition according to any one of the preceding claims wherein the composition is a fluid liquid at 25 °C and atmospheric pressure.
11. 11. The composition according to any one of the preceding claims wherein the composition comprises water in amount of 10 to 96% by weight of the composition, preferably from 42 to 88% by weight of the composition.
12. 12. A method of providing the skin benefits selected from the group consisting of enhancing filaggrin production in the skin, improving skin barrier health, upregulating the expression of filaggrin gene comprising a step of topically applying to the skin the composition of any one of the preceding claims.
13. 13. Use of the composition of any one of the preceding claims 1 to 11 for providing the skin benefits selected from the group consisting of enhancing filaggrin production in the skin, improving skin barrier health, upregulating the expression of filaggrin gene.
14. 14. Use of carboxymethyl cysteine compound for providing benefits selected from the group consisting of enhancing filaggrin production in the skin, improving skin barrier health, upregulating the expression of filaggrin 2 gene.

Description

A PERSONAL CARE COMPOSITION Field of the Invention The present invention relates to a personal care composition comprising carboxymethyl cysteine compound and moringa oil. It was unexpectedly found that such composition is capable of synergistically upregulating the expression of FLG2 gene. Background of the Invention Skin is an organ that protects the body from external stressors like heat, UV, pollutants, allergens, pathogens etc. It also prevents loss of moisture. The protective role of skin is carried out by epidermal or skin barrier. The skin barrier consists of different layers of stratified cells and the outermost layer consists of corneocytes embedded in a layer of lipids. The major constituents of corneocytes are proteins like keratin, filaggrin etc. These proteins are essential for the formation and maintenance of a healthy skin barrier. Any damage or dysfunction of these proteins lead to defective barrier and associated skin conditions like dryness, atopic dermatitis increased susceptibility to skin infections, inability to support a healthy microbiome etc. Among the skin proteins, filaggrin play a pivotal role in maintaining healthy barrier. It is a structural protein involved in the terminal differentiation of keratinocytes. Proteolysis of filaggrin releases free amino acids and these free amino acids are the important constituents of natural moisturization factor (NMF) which imparts skin hydration. Filaggrin maintains barrier integrity thereby preventing entry of pathogens, and other irritants and allergens. Loss of filaggrin results in skin conditions like atopic dermatitis, an inflammatory skin condition manifested as dry, itchy and flaky skin. Filaggrin also helps in maintaining a healthy microbiome by protecting the skin from pathogens. One of the mechanisms by which moisturizers function is by boosting filaggrin in skin. Increasing filaggrin levels on skin is a well-accepted approach for maintaining or improving skin health. Upregulating the expression of filaggrin genes typically leads to an increase in filaggrin production. Therefore, the present inventors have recognized that there is a need to develop solution to enhance the expression of filaggrin 2 gene (FLG2). It was surprisingly found that by combining carboxymethyl cysteine and moringa oil, the expression of FLG2 gene was significantly upregulated. Summary of the Invention In a first aspect, the present invention is directed to a personal care composition comprising carboxymethyl cysteine compound and moringa oil wherein the carboxymethyl cysteine compound is present in amount of at least 0.00001% and no greater than 10% by weight of the composition. In a second aspect, the present invention is directed to a method of providing the skin benefits selected from the group consisting of enhancing filaggrin production in the skin, improving skin barrier health, upregulating the expression of filaggrin gene comprising a step of topically applying to the skin the composition of the composition of the present invention. In a third aspect, the present invention is directed to use of the composition of the present invention for providing the skin benefits selected from the group consisting of enhancing filaggrin production in the skin, improving skin barrier health, upregulating the expression of filaggrin gene. All other aspects of the present invention will more readily become apparent upon considering the detailed description and examples which follow. Detailed Description of the Invention Except in the examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material or conditions of reaction, physical properties of materials and/or use may optionally be understood as modified by the word “about”. All amounts are by weight of the composition, unless otherwise specified. It should be noted that in specifying any range of values, any particular upper value can be associated with any particular lower value. For the avoidance of doubt, the word “comprising” is intended to mean “including” but not necessarily “consisting of’ or “composed of’. In other words, the listed steps or options need not be exhaustive. The disclosure of the invention as found herein is to be considered to cover all embodiments as found in the claims as being multiply dependent upon each other irrespective of the fact that claims may be found without multiple dependency or redundancy. Where a feature is disclosed with respect to a particular aspect of the invention (for example a composition of the invention), such disclosure is also to be considered to apply to any other aspect of the invention (for example a method of the invention) mutatis mutandis. The carboxymethyl cysteine compound refers to compound selected from carboxymethyl cysteine, salt of carboxymethyl cysteine, ester of carboxymethyl cysteine, amide of carboxymethyl cysteine or a mixture thereof. Preferably, the carboxymethyl cysteine compound comprises